FindTrial
Sign In

Application and promotion of cross-modal intelligent analysis system in molecular diagnosis and precision treatment decision-making of lung cancer

Application and promotion of cross-modal intelligent analysis system in molecular diagnosis and precision treatment decision-making of lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036020
Enrollment
Unknown
Registered
2020-08-21
Start date
2021-10-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Gold Standard:Molecular diagnostic evaluation
Index test:Cross-modal&#32
intelligent&#32
analysis&#32
system

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced non-small cell lung cancer diagnosed by biopsy in Shanghai Pulmonary Hospital; 2. Upon the recommendation of the attending doctor and the patient's consent, EGFR driver gene mutation and TMB testing are planned; 3. The patient participated voluntarily and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have received targeted therapy and immunotherapy in the past; 2. The patient withdrew voluntarily midway.

Design outcomes

Primary

MeasureTime frame
Accuracy;—

Secondary

MeasureTime frame
Sensitivity;Specificity;AUC;Positive predictive value;Negative predictive value;Progerssion-free Survival;—

Countries

China

Contacts

Public ContactWu Chunyan

Shanghai Pulmonary Hospital

1831228@tongji.edu.cn+86 15618977421

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026